Sotagliflozin shows benefit for difficult-to-treat form of heart failure
Patients with both diabetes and heart failure who were treated with sotagliflozin, a novel investigational drug for diabetes, for a median of nine to 16 months experienced reductions of 22% to 43% in the risk of death or ...
May 17, 2021
0
10